First clinical isolation of Purpureocillium lilacinum in a pediatric oncological patient in Ecuador
Oxford Medical Case Reports · 03.08.2026 · 2026 (8)
DOI: 10.1093/omcr/omag129 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oxford Medical Case Reports, online erschienen am 03.08.2026. Verfasst von Johana Salgado und 4 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Laboratory, Hospital Oncológico SOLCA Núcleo de Quito, Av. Eloy Alfaro 5394 y los Pinos, Quito 170514, Ecuador. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Purpureocillium lilacinum is a ubiquitous environmental fungus widely utilized as an agricultural biocontrol agent, but it is increasingly recognized as an opportunistic human pathogen. While invasive fungal infections caused by this microorganism have been documented globally, disseminated systemic presentations in pediatric oncology remain exceptionally rare and carry high mortality rates. Case Description We report the case of an 11-year-old female patient with a high-grade osteosarcoma who developed high-risk febrile leukopenia during chemotherapy. Blood cultures from both a subcutaneous port and peripheral blood turned positive for both yeast-like and hyphal structures, which were further identified by DNA barcoding (ITS and EF1a regions) as P. lilacinum. The patient exhibited concurrent multiorgan dissemination, including hyperchromic scaling skin lesions in the perianal region and limbs, as well as diffuse bilateral pulmonary micronodules confirmed via video-thoracoscopy biopsy. Despite initial treatment with amphotericin B and fluconazole, clinical resolution was successfully achieved only after optimizing the antifungal regimen with oral voriconazole. The patient fully recovered and remains stable.
Conclusions
To our knowledge, this represents the first clinical isolation and reported case of disseminated systemic P. lilacinum infection in a pediatric oncological patient in Ecuador. This case highlights the aggressive nature of this pathogen in immunosuppressed children, the challenge of its diagnosis due to the lack of specialized infrastructure for antifungal susceptibility testing, and the critical importance of a multidisciplinary approach and prompt, targeted first-line therapy with voriconazole to ensure survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Microbiology Laboratory, Hospital Oncológico SOLCA Núcleo de Quito, Av. Eloy Alfaro 5394 y los Pinos, Quito 170514, Ecuador.
- Molecular Biology and Flow Cytometry, Hospital Oncológico SOLCA Núcleo de Quito, Av. Eloy Alfaro 5394 y los Pinos, Quito 170514, Ecuador.
- Grupo de Investigación y Desarrollo de la Biotecnología BioSin-Biociencias, José de Ascázubi y Las Brisas, Quito 170801, Ecuador.
- Pediatric Oncology Service, Hospital Oncológico SOLCA Núcleo de Quito, Av. Eloy Alfaro 5394 y los Pinos, Quito 170514, Ecuador.
ORCID-Profile: Johana Salgado, Estefanía Mariño-Brito, Francisco Mosquera-Yuqui, Analia Ruales Guerra, Jennia Joanna Acebo Arcentales
Zitieren
APA
Salgado, J., Mariño-Brito, E., Mosquera-Yuqui, F., Ruales Guerra, A., & Acebo Arcentales, J. J. (2026). First clinical isolation of Purpureocillium lilacinum in a pediatric oncological patient in Ecuador. Oxford Medical Case Reports, 2026(8). https://doi.org/10.1093/omcr/omag129
Vancouver
Salgado J, Mariño-Brito E, Mosquera-Yuqui F, Ruales Guerra A, Acebo Arcentales JJ. First clinical isolation of Purpureocillium lilacinum in a pediatric oncological patient in Ecuador. Oxford Medical Case Reports. 2026;2026(8). doi:10.1093/omcr/omag129
BibTeX
@article{Salgado2026,
author = {Salgado, Johana and Mariño-Brito, Estefanía and Mosquera-Yuqui, Francisco and Ruales Guerra, Analia and Acebo Arcentales, Jennia Joanna},
title = {First clinical isolation of Purpureocillium lilacinum in a pediatric oncological patient in Ecuador},
journal = {Oxford Medical Case Reports},
year = {2026},
volume = {2026},
number = {8},
doi = {10.1093/omcr/omag129}
}
EUVIMED